A Phase I, Open-Label, Dose Finding Study of Calaspargase Pegol-Mnkl in Combination With Cobimetinib in Locally-Advanced or Metastatic Pancreatic Cancer
Latest Information Update: 16 Nov 2023
At a glance
- Drugs Calaspargase pegol (Primary) ; Cobimetinib (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions
- Acronyms Casper
- 28 Mar 2023 Planned number of patients changed from 24 to 15.
- 21 Jan 2023 Trial design presented at the 2023 Gastrointestinal Cancers Symposium.
- 25 Aug 2022 Status changed from not yet recruiting to recruiting.